ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board
September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
- September 1, 2021 ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that Jeffrey Abbey, MBA, JD, has been appointed as Chief Operating Officer.
- Under Mr. Abbeys leadership, Argos Therapeutics successfully completed an IPO on NASDAQ, as well as a pivotal Phase 3 clinical trial in kidney cancer.
- I am looking forward to working with the team at ImmunOs and its advisory boards, said Jeffrey Abbey, MBA, JD, COO of ImmunOs Therapeutics.
- ImmunOs Therapeutics lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and activates anti-tumor responses.